Uniphar | Access’ Post

At #AMCPNexus next week? Discover how Folia can help you boost access by describing the full burden of a condition and the impact of a new therapy on daily lived experiences, including: 1) Longitudinal view of heterogeneous populations 2) Real-time flare data 3) Comprehensive utilization data and treatment effectiveness 4) Real-world medication utilization and efficacy outside of clinic visits Book a meeting with Jason Wolf, MBA: https://lnkd.in/gdz97PGu #payervalue #marketaccess #rwd

The CAR-T therapy market is maturing which is great for people needing these therapies. This article discusses the changes from the therapies themselves, support staff, and hospitals to hotels. https://lnkd.in/gXMW_Hr7

Delays in clinical drug trials can lead to increased costs, extended market delivery times, and impact patient access to new treatments. However, with the right strategies and partnerships, these setbacks can be minimised or even avoided. Our latest blog delves into the common causes of delays, such as startup timelines and patient recruitment, and how the ANZ region stands out in rapid trial initiation and effective recruitment. 📚 Learn more in our latest blog: https://lnkd.in/g6U7UG6P #ClinicalTrials #DrugDevelopment #PharmaSols #ANZInnovation #PatientCare #ResearchEfficiency

Discover the Future of Healthcare Delivery with #PrefilledSyringes! Join us and explore our blog, which highlights the following key points: • #MarketGrowth: Projected to reach $22.8 billion by 2029. • #WhyItMatters: Enhanced safety, precision, and convenience for patients. • #DrivingFactors: Innovations in biology, rising chronic disease prevalence. • #KeyPlayers: BD, Baxter, Stevanato Group, and more leading the charge. Explore further by visiting the blog's link: https://bit.ly/3VYJhjU #InjectionDevices #MedTech #PharmaTech #PatientSafety #MarketTrends #MarketGrowth

The growing specialty drug market indicates more than a shift in treatment paradigms—it's showing a profound evolution in our approach to healthcare by emphasizing personalized solutions tailored to individual needs and conditions. This trajectory tells us that medical interventions are becoming increasingly targeted, efficient, and, ultimately, more effective. This could potentially offer hope for improved outcomes and quality of life across more diverse patient populations, though the growing market doesn't inherently mean easier access for patients. #MarketAccess #SpecialtyDrugs #RareDiseases

The Rising Costs of Rare Drug Treatments: A Struggle for Healthcare Systems Discover the challenges faced by healthcare systems as the cost of rare drug treatments continues to rise. Explore the case of Alexion, which pushed the limits by charging $2.7 million per year per patient for an ultra-rare drug with only 80 patients. Understand the impact on healthcare budgets and the potential consequences for patients needing expensive therapies. #HealthcareChallenges #RareDrugTreatment #HealthcareBudgets #AlexionCaseStudy #PatientSupport #ExpensiveTherapies #MedicalCosts #HealthcareSystem #DrugAffordability #HealthcareManagement

The Rising Costs of Rare Drug Treatments: A Struggle for Healthcare Systems Discover the challenges faced by healthcare systems as the cost of rare drug treatments continues to rise. Explore the case of Alexion, which pushed the limits by charging $2.7 million per year per patient for an ultra-rare drug with only 80 patients. Understand the impact on healthcare budgets and the potential consequences for patients needing expensive therapies. #HealthcareChallenges #RareDrugTreatment #HealthcareBudgets #AlexionCaseStudy #PatientSupport #ExpensiveTherapies #MedicalCosts #HealthcareSystem #DrugAffordability #HealthcareManagement

'CAR-T therapies face challenges despite initial successes in the U.S.' - Growth potential hindered by healthcare infrastructure limitations. - Logistical challenges in treatment processes and patient monitoring. - Patients must stay near treatment centers for a month, posing a significant hurdle. How might the challenges outlined in the article, particularly regarding healthcare infrastructure and referral barriers, apply to the UK's healthcare system and the adoption of CAR-T therapies? https://lnkd.in/e6b6ZPpR

A pharmaceutical manufacturer with a recently launched therapy needed a better understanding of how payers determined utilization management for expensive new treatments in the rare disease category. The manufacturer needed to understand which factors influence payers to cover a product’s off-label use, identify appropriate market access analogs for its therapy, and determine whether to seek a new FDA indication in rare diseases. MMIT’s Engage solution solves these challenges, which allows payer responses to be viewed in real-time. What happened next? Check out the full Use Case to find out: https://ow.ly/ix8Z50QVE5U #Pharma #PharmaManufacturing #Payers #RareDiseases #MarketAccess #FDAIndication